AMC Entertainment
GameStop
Zomedica
Churchill Capital Corp IV
Ideanomics
Nokia
QuantumScape
Ford Motor
Aphria
Atara Biotherapeutics (ATRA) stock forecast for 2025
The forecast has been updated: September 27, 2021 12:38
Atara Biotherapeutics stock price online today
Analyst Target Price
33.38Dividend Date
-Ex Dividend Date
-Last Split Factor
NoneLast Split Date
-Should you buy or sell Atara Biotherapeutics stock stock today? What is the projected target price level for 2025? How much will it cost in 2025? Atara Biotherapeutics stock Stock Monthly Prediction for January, February, March, April, May, July, July, August, September, October, November and December 2025.
We predict the dynamics of the stock market value using resonant artificial intelligence systems.
Technical, fundamental analyzes, news background, general geopolitical situation in the world and other factors are taken into account.
Forecasts are adjusted once a day taking into account the price change of the previous day.
To date, analysts have a $33.38 target price for Atara Biotherapeutics stock stock.
Today 200 Day Moving Average is the support level (14.34 $).
50 Day Moving Average is the support level (14.58 $).
ATRA Forecast for 2025
| Month | Rate Forecast | MIN Rate | MAX Rate | Volati- lity, % |
|---|---|---|---|---|
| Jan | 16.82 | 16.20 | 18.01 | 10.09 % |
| Feb | 17.21 | 16.40 | 17.95 | 8.63 % |
| Mar | 17.76 | 16.65 | 19.08 | 12.73 % |
| Apr | 17.36 | 16.75 | 18.52 | 9.56 % |
| May | 17.69 | 16.42 | 18.67 | 12.05 % |
| Jun | 17.76 | 16.65 | 18.59 | 10.43 % |
| Jul | 18.59 | 17.27 | 19.97 | 13.51 % |
| Aug | 18.43 | 17.43 | 20.20 | 13.69 % |
| Sep | 18.65 | 17.26 | 19.37 | 10.86 % |
| Oct | 18.18 | 17.00 | 19.14 | 11.17 % |
| Nov | 19.10 | 18.59 | 20.11 | 7.52 % |
| Dec | 20.08 | 19.50 | 21.24 | 8.17 % |
The forecasts table above shows the forecast values of the company's stock price for each month. The Rate Forecast column displays the Optimal Average Forecast Price. The MIN Rate column displays a pessimistic forecast for this month. “MAX Rate” is an optimistic forecast. The % Volatility column represents the approximate monthly volatility of Atara Biotherapeutics stock.
Atara Biotherapeutics overview
Atara Biotherapeutics Address
611 GATEWAY BLVD, SUITE 900, SOUTH SAN FRANCISCO, CA, USMarket Capitalization
1 440 879 000 $EBITDA
-279 340 992PE Ratio
NonePEG Ratio
0Dividend Per Share
NoneDividend Yield
0EPS
-3.628Quarterly Earnings Growth YOY
0Quarterly Revenue Growth YOY
0Trailing PE
0Forward PE
0EV To Revenue
134.96EV To EBITDA
052 Week High
26.152 Week Low
11.8150 Day Moving Average
14.58200 Day Moving Average
14.34Shares Outstanding
84758000Shares Float
61193000Shares Short Prior Month
12220300Short Ratio
16.78Percent Insiders
0.571Percent Institutions
103.19Atara Biotherapeutics stock forecast for this year
Atara Biotherapeutics stock forecast for Jan 2025.
Estimated Average Forecasted Atara Biotherapeutics Price: 16.82. Negative monthly dynamics of the instrument is expected with 10.085% volatility is expected.
Pessimistic forecast: 16.20
Optimistic: 18.01
Atara Biotherapeutics stock forecast for Feb 2025.
Estimated Average Forecasted Atara Biotherapeutics Price: 17.21. Positive monthly dynamics of the instrument is expected with 8.627% volatility is expected.
Pessimistic forecast: 16.40
Optimistic: 17.95
Atara Biotherapeutics stock forecast for Mar 2025.
Estimated Average Forecasted Atara Biotherapeutics Price: 17.76. Positive monthly dynamics of the instrument is expected with 12.733% volatility is expected.
Pessimistic forecast: 16.65
Optimistic: 19.08
Atara Biotherapeutics stock forecast for Apr 2025.
Estimated Average Forecasted Atara Biotherapeutics Price: 17.36. Negative monthly dynamics of the instrument is expected with 9.558% volatility is expected.
Pessimistic forecast: 16.75
Optimistic: 18.52
Atara Biotherapeutics stock forecast for May 2025.
Estimated Average Forecasted Atara Biotherapeutics Price: 17.69. Positive monthly dynamics of the instrument is expected with 12.055% volatility is expected.
Pessimistic forecast: 16.42
Optimistic: 18.67
Atara Biotherapeutics stock forecast for Jun 2025.
Estimated Average Forecasted Atara Biotherapeutics Price: 17.76. Positive monthly dynamics of the instrument is expected with 10.432% volatility is expected.
Pessimistic forecast: 16.65
Optimistic: 18.59
Atara Biotherapeutics stock forecast for Jul 2025.
Estimated Average Forecasted Atara Biotherapeutics Price: 18.59. Positive monthly dynamics of the instrument is expected with 13.515% volatility is expected.
Pessimistic forecast: 17.27
Optimistic: 19.97
Atara Biotherapeutics stock forecast for Aug 2025.
Estimated Average Forecasted Atara Biotherapeutics Price: 18.43. Negative monthly dynamics of the instrument is expected with 13.686% volatility is expected.
Pessimistic forecast: 17.43
Optimistic: 20.20
Atara Biotherapeutics stock forecast for Sep 2025.
Estimated Average Forecasted Atara Biotherapeutics Price: 18.65. Positive monthly dynamics of the instrument is expected with 10.863% volatility is expected.
Pessimistic forecast: 17.26
Optimistic: 19.37
Atara Biotherapeutics stock forecast for Oct 2025.
Estimated Average Forecasted Atara Biotherapeutics Price: 18.18. Negative monthly dynamics of the instrument is expected with 11.170% volatility is expected.
Pessimistic forecast: 17.00
Optimistic: 19.14
Atara Biotherapeutics stock forecast for Nov 2025.
Estimated Average Forecasted Atara Biotherapeutics Price: 19.10. Positive monthly dynamics of the instrument is expected with 7.523% volatility is expected.
Pessimistic forecast: 18.59
Optimistic: 20.11
Atara Biotherapeutics stock forecast for Dec 2025.
Estimated Average Forecasted Atara Biotherapeutics Price: 20.08. Positive monthly dynamics of the instrument is expected with 8.170% volatility is expected.
Pessimistic forecast: 19.50
Optimistic: 21.24
Other Healthcare sector assets
| Name | Symbol | Last Close Price | Change |
|---|---|---|---|
 Abbott Laboratories
|
ABT | 124.37 (24.09.2021) | -0.74 % |
 AbbVie Inc.
|
ABBV | 107.07 (24.09.2021) | -0.27 % |
 Aeterna Zentaris Inc.
|
AEZS | 0.602564 (24.09.2021) | -3.68 % |
 Allakos Inc.
|
ALLK | 108.17 (24.09.2021) | -2.05 % |
 Allogene Therapeutics, Inc.
|
ALLO | 25.66 (24.09.2021) | -7.16 % |
 Amgen Inc.
|
AMGN | 213.61 (24.09.2021) | -0.67 % |
|
Aphria Inc.
|
APHA | 15.38 (07.05.2021) | 0.00 % |
|
Atara Biotherapeutics, Inc.
|
ATRA | 17 (24.09.2021) | -1.73 % |
 Aurora Cannabis Inc.
|
ACB | 5.95 (24.09.2021) | -3.25 % |
 Becton Dickinson and Company
|
BDX | 253.18 (24.09.2021) | -0.25 % |
 Biogen Inc.
|
BIIB | 291.71 (24.09.2021) | -0.51 % |
 Biohaven Pharmaceutical Holding Company Ltd.
|
BHVN | 133.38 (24.09.2021) | -1.60 % |
 BioNTech SE
|
BNTX | 333.48 (24.09.2021) | -5.53 % |
 bluebird bio, Inc.
|
BLUE | 18.44 (24.09.2021) | -1.18 % |
 Boston Scientific Corp.
|
BSX | 44.7 (24.09.2021) | -0.67 % |
 Bristol-Myers Squibb Company
|
BMY | 60.23 (24.09.2021) | -0.66 % |
 Canopy Growth Corp.
|
CGC | 13.91 (24.09.2021) | -4.46 % |
 Castle Biosciences, Inc.
|
CSTL | 72.44 (24.09.2021) | -3.35 % |
|
CLOVER HEALTH INVESTMENTS, CORP
|
CLOV | 7.73 (24.09.2021) | -2.15 % |
 Eli Lilly and Company
|
LLY | 231.68 (24.09.2021) | -0.22 % |
 Emergent BioSolutions Inc.
|
EBS | 52.39 (24.09.2021) | -2.69 % |
 Exelixis, Inc.
|
EXEL | 20.35 (24.09.2021) | -0.73 % |
 G1 Therapeutics, Inc.
|
GTHX | 15.1 (24.09.2021) | -1.44 % |
 Gilead Sciences, Inc.
|
GILD | 71.19 (24.09.2021) | -0.70 % |
 GlaxoSmithKline plc
|
GSK | 38.39 (24.09.2021) | -2.41 % |
 GoodRx Holdings, Inc.
|
GDRX | 44.13 (24.09.2021) | -4.75 % |
 GW Pharmaceuticals plc.
|
GWPH | 218.96 (05.05.2021) | 0.00 % |
 Incyte Corp.
|
INCY | 69 (24.09.2021) | -1.12 % |
 Inovio Pharmaceuticals, Inc.
|
INO | 7.76 (24.09.2021) | -3.36 % |
 Johnson & Johnson
|
JNJ | 164.36 (24.09.2021) | -0.30 % |
 Medtronic plc.
|
MDT | 130.02 (24.09.2021) | -0.47 % |
 Merck & Co., Inc.
|
MRK | 73.61 (24.09.2021) | 0.77 % |
 Moderna, Inc.
|
MRNA | 430.14 (24.09.2021) | -5.38 % |
 Novartis AG
|
NVS | 82.93 (24.09.2021) | -0.77 % |
 Novavax, Inc.
|
NVAX | 248.16 (24.09.2021) | -3.55 % |
 ObsEva SA
|
OBSV | 3.15 (24.09.2021) | -0.32 % |
 OrganiGram Holdings Inc.
|
OGI | 2.42 (24.09.2021) | -3.20 % |
 Pfizer Inc.
|
PFE | 43.94 (24.09.2021) | -0.57 % |
 Regeneron Pharmaceuticals, Inc.
|
REGN | 638.9 (24.09.2021) | -1.18 % |
 Sanofi
|
SNY | 47.94 (24.09.2021) | -1.60 % |
 Schrodinger, Inc.
|
SDGR | 57.95 (24.09.2021) | -4.23 % |
 Senseonics Holdings, Inc.
|
SENS | 3.57 (24.09.2021) | -4.29 % |
 Sorrento Therapeutics, Inc.
|
SRNE | 7.83 (24.09.2021) | -3.09 % |
 Stryker Corp.
|
SYK | 276.64 (24.09.2021) | 0.17 % |
 Sundial Growers Inc.
|
SNDL | 0.673 (24.09.2021) | -4.06 % |
 Teva Pharmaceutical Industries Lim. (TEVA)
|
TEVA | 8.95 (24.09.2021) | -1.10 % |
 Thermo Fisher Scientific Inc.
|
TMO | 609.78 (24.09.2021) | 0.25 % |
 Tilray, Inc.
|
TLRY | 11.67 (24.09.2021) | -2.91 % |
 UnitedHealth Group, Inc.
|
UNH | 407.08 (24.09.2021) | -0.23 % |
 Veeva Systems Inc.
|
VEEV | 299.93 (24.09.2021) | 0.41 % |
|
Zomedica Corp.
|
ZOM | 0.5178 (24.09.2021) | -2.30 % |
 Zynerba Pharmaceuticals, Inc.
|
ZYNE | 4.46 (24.09.2021) | -1.55 % |
Denial of responsibility:
The portal leoprophet.com is not responsible for the loss of your money as a result of your use of the information contained on the site, including data, quotes, charts and forecasts. Operations in the stock, foreign exchange and commodity markets involve a high level of risk, and you are solely responsible for your operations. Only speculate with money that you can afford to lose. All prices and forecasts for stocks, indices, futures are indicative and should not be trade dependent. The portal is not responsible for any losses that you may incur as a result of using this data.